Health Catalyst, Inc.

HCAT
About the company

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services.

Country: United StatesPrice: $1.51Market Cap: $115.0M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Buffett, Piotroski and Marks object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #3033 (Top 97.9%)PASSFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-12

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Buffett, Piotroski and Marks object

    LT Debt vs Net Current AssetsLT Debt $0.0M vs NCA $54.8M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.62, IC: -7.3x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt$53.7M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change17.60% -> 30.17%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.70
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-7.3x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 7✗ 21▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio0.4x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-292.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-292.1%, ROC=-503.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)148.8x
    ✗Dreman< 8x
    Price / Book Value per Share0.4x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-118.1%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-0.2%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=0.4x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low152% of trailing low ($1.00)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-175.74%; #5625/6340 (top 88.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.2660; #1122/6449 (top 17.4%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-45.6%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+2.3671; #960/5247 (top 18.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+22.36%; #255/4519 (top 5.6%)
    ✓OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+51.56%; #629/6202 (top 10.1%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 3✗ 10▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-12.13 (2017) -> $-2.55 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth3.6%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 44.5% -> 48.7%, operating margin -42.9% -> -51.7%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR10.5%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 4✗ 31▾

    15 of 16 flag HCAT's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)0/10 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/10 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-37.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-51.7% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-128.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-138.8%
    ✗Lynch> 15%
    EBIT / Enterprise Value-292.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-292.1%, ROC=-503.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-35.41%
    ✗PiotroskiROA > 0
    ROA Change YoY-8.09% -> -35.41% (delta: -27.32%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=0.15%, ROA=-35.41%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY45.9% -> 48.7%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-57.0%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-138.8%
    ✗Dreman> 12%
    Margin of SafetyP/B=0.4x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-41.2% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-65.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-138.8%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-42.9% (2023) -> -51.7% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 44.5% -> 48.7%, operating margin -42.9% -> -51.7%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-175.74%; #5625/6340 (top 88.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+30.18%; #1420/3702 (top 38.4%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-138.81%; #4747/5226 (top 90.8%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0887; #3329/5884 (top 56.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/9 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts13% pass✓ 2✗ 14▾

    Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #3033✓PiotroskiPASS (F-Score 5)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1784/2370 (Top 75.3%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag HCAT's efficiency — Graham, Buffett, Greenblatt +3 more

    Current Ratio1.70
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-22.2%
    ✗Buffett> 10%
    ROIC - WACC-32.2%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-503.5%
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.43 -> 1.89
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.36x -> 0.62x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities1.70
    ✓Dreman> 1.5
    Return on Invested Capital-97.1%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-16.8%; FY2024: ROIC=-7.4%; FY2025: ROIC=-31.8%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -31.8%)
    ✗SleepROIC > 12% in a majority of years
  • Cash Flow30% pass✓ 5✗ 7▾

    7 of 10 flag HCAT's cash flow — Buffett, Lynch, Dreman +4 more

    Free Cash Flow Proxy$-128.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-0.2M
    ✗LynchPositive and growing
    Operating Cash Flow$0.7M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=0.15%, ROA=-35.41%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)148.8x
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-0.2%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive1/9 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap23.6%
    ✓Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency2/9 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$25.7M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+22.36%; #255/4519 (top 5.6%)
    ✓OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Business Services
Size: Micro Cap($115.0M)
Revenue: $311.1M+1.5% YoY
Net Income: $178.0M-156.1% YoY

Financial Snapshot

Operating Margin-51.7%
Return on Equity-72.4%
Debt / Equity0.62
Current Ratio1.89
EPS (Diluted)$-2.55
Buybacks (1y)$5.0M
Buybacks (2y)$5.0M
Shares Retired−12.5% / −23.0% 2y

Similar Companies

ADPAUTOMATIC DATA PROCESSING INC
$122.3B
EAELECTRONIC ARTS INC.
$52.9B
RBRKRubrik, Inc.
$22.6B
ACMAECOM
$9.1B

Shareholder Return

Fiscal 2025

Issued 12.5% of shares last year, 23.0% issued over two.

Buybacks
$5.0M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-12
FY 2024
Sources
  • 10-K · 2025-02-26
FY 2023
Sources
  • 10-K · 2024-02-22
FY 2022
Sources
  • 10-K · 2023-02-28
FY 2021
Sources
  • 10-K · 2022-03-01
Market Cap$115.0Mcurrent------$154.9Mest.$360.6Mest.$572.2Mest.$775.7Mest.$1.6Best.
Revenue$272.2M↓14%$56.3M↓26%$70.5M↓13%$70.8M↓11%$311.1M↑1%$306.6M↑4%$295.9M↑7%$276.2M↑14%$241.9M
Operating Income-$178.9M↓94%$50.1M↑386%-$36.5M↑2%-$106.5M↓428%-$160.9M↓130%-$69.8M↑45%-$126.9M↑9%-$140.0M↑3%-$143.7M
Net Income-$202.1M↓88%$40.5M↑282%-$40.5M↑1%-$111.0M↓368%-$178.0M↓156%-$69.5M↑41%-$118.1M↑14%-$137.4M↑10%-$153.2M
EPS (Diluted)--$0.53↑266%$-0.55↑7%$-1.53↓337%$-2.55↓122%$-1.15↑45%$-2.09↑21%$-2.63↑19%$-3.23
Gross Margin————48.7%↑6%45.9%↑3%44.5%↓8%48.2%↓1%48.6%
Operating Margin-65.7%↓125%89.1%↑488%-51.8%↓13%-150.5%↓492%-51.7%↓127%-22.8%↑47%-42.9%↑15%-50.7%↑15%-59.4%
ROE-138.8%↓328%———-72.4%↓280%-19.0%↑41%-32.2%-32.3%↓10%-29.3%
Total Debt$0↓100%$0↓100%$153.5M$153.4M↓60%$153.3M↓60%$382.4M↑68%$228.0M↑1%$226.5M↑25%$180.9M
Shareholders' Equity$145.6M↓56%$145.6M↓56%$100.8M↓71%$138.1M↓63%$245.8M↓33%$365.2M$366.9M↓14%$425.0M↓19%$522.1M
Current Ratio1.70↓10%1.70↓10%2.70↑48%1.69↑36%1.89↑32%1.43↓68%4.42↓15%5.18↓5%5.46
Debt / Equity0.00↓100%0.00↓100%1.52↑246%1.11↑9%0.62↓40%1.05↑68%0.62↑17%0.53↑54%0.35
Operating Cash Flow$26.8M↑311%-$1.9M↓304%$275.0K↑103%$18.5M↑6511%$731.0K↓95%$14.6M↑144%-$33.1M↑6%-$35.3M↓53%-$23.1M
Free Cash Flow$25.7M-$2.0M↓182%-$70.0K$18.2M↑4760%-$237.0K↓102%$12.9M↑138%-$34.3M↑8%-$37.4M↓12%-$33.6M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Business Services

HCAT vs Peers — Financial Grading

Revenue$311.1MBottom 25%
Net Income$178.0MBottom 25%
ROE-72.4%Bottom 25%
D/E0.62Top 25%
Op. Margin-51.7%Bottom 25%
Curr. Ratio1.89Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
AUTOMATIC DATA PROCESSING INCADP$122.3B$309.93$21.9B$4.4B73.2%0.8224.2%1.054/95/93/70/3F-Score 65/11
ELECTRONIC ARTS INC.EA$52.9B$209.70$7.5B$887.0M13.1%0.2215.4%1.051/94/94/70/3F-Score 66/11
Rubrik, Inc.RBRK$22.6B$109.88$1.3B$348.8M67.1%—-26.2%1.691/90/92/70/3F-Score 62/11
AECOMACM$9.1B$70.50$16.1B$561.8M22.5%1.096.4%1.141/93/93/71/3F-Score 82/11
COMMVAULT SYSTEMS INCCVLT$6.2B$152.07$1.2B$70.7M942.8%—6.3%1.951/92/94/70/3F-Score 66/11
WPP plcWPP$6.0B$27.79$18.2B$289.5M-8.5%1.942.8%0.891/92/91/70/3F-Score 32/11
VARONIS SYSTEMS INCVRNS$5.6B$48.94$623.5M$129.3M-21.6%0.76-23.5%1.971/90/91/70/3F-Score 51/11
ROBERT HALF INC.RHI$4.3B$42.00$5.4B$133.0M10.4%—1.4%1.532/95/91/70/3F-Score 52/11